SRK 373
Alternative Names: SRK-373Latest Information Update: 14 Aug 2024
At a glance
- Originator Scholar Rock
- Class Antibodies; Antifibrotics
- Mechanism of Action Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis
Most Recent Events
- 09 Aug 2024 Preclinical development for Fibrosis is ongoing in the US
- 09 Jan 2023 Scholar Rock plans for an IND-enabling studies in Fibrosis
- 19 Dec 2021 Gilead Sciences terminates agreement with Scholar Rock to co-promote and co-develop Transforming growth factor beta 1 activation inhibitors for Fibrosis